12 unchanged sentences
Based on our assessment, the Company’s ma nagement believes that its internal controls over financial reporting were effective as of March 29, 2025.
−Removed: The Acquisition of OpSens Inc.
−Removed: On December 12, 2023, the Company completed its acquisition of OpSens.
−Removed: In accordance with the SEC Staff’s interpretative guidance for newly acquired businesses, we are permitted to omit an assessment of an acquired business’s internal control over financial reporting from our assessment of internal control for up to one year from the acquisition date.
−Removed: OpSens represented approximately 1% of both the Company’s total net revenues in fiscal 2024 and total assets as of March 30, 2024.
−Removed: As such, we have excluded OpSens from our annual assessment of internal control over financial reporting as of March 30, 2024.
Ernst & Young, LLP, an independent registered public accounting firm, has issued an attestation report on the effectiveness of our internal control over financ ial reporting.
6 unchanged sentences
Report of Independent Registered Public Accounting Firm
−Removed: To the Stockholders and Board of Directors of Haemonetics Corporation
+Added: To the Stockholders and the Board of Directors of Haemonetics Corporation
Opinion on Internal Control Over Financial Reporting
1 unchanged sentence
In our opinion, Haemonetics Corporation and subsidiaries (the Company) maintained, in all material respects, effective internal control over financial reporting as of March 29, 2025, based on the COSO criteria.
−Removed: As indicated in the accompanying Management’s Annual Report on Internal Control over Financial Reporting, management’s assessment of and conclusion on the effectiveness of internal control over financial reporting did not include the internal controls of OpSens Inc., which is included in the 2024 consolidated financial statements of the Company and constituted approximately 1% of total assets as of March 30, 2024 and 1% of net revenues for the year then ended.
−Removed: Our audit of internal control over financial reporting of the Company also did not include an evaluation of the internal control over financial reporting of OpSens Inc.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the 2025 consolidated financial statements of the Company and our report dated May 21, 2025 expressed an unqualified opinion thereon.
Basis for Opinion
−Removed: The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Annual Report on Internal Control over Financial Reporting.
+Added: T he Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Annual Report on Internal Control over Financial Reporting.
Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit.
21 unchanged sentences
Expiration Date (3)
−Removed: Anila Lingamneni , EVP, Chief Technology Officer
+Added: Strong , President, Global Hospital
* Intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934.
3 unchanged sentences
(3) Except as otherwise indicated by footnote, each trading arrangement expires upon the earlier of (a) completion of all authorized transactions thereunder and (b) the expiration date listed above.
−Removed: (4) Includes 7,070 target shares subject to a performance share unit (“PSU”) award previously granted to Ms.
−Removed: Lingamneni on May 18, 2021.
+Added: (4) Includes 8,246 target shares subject to a performance share unit (“PSU”) award previously granted to Mr.
+Added: Strong on May 16, 2022.
The actual number of shares to be earned under the PSU award, and subject to sale under this trading arrangement, may range from 0% to a maximum of 200% of the target award depending upon the Company’s total shareholder return relative to the components of the S&P MidCap 400 index during a three-year performance period from May 16, 2022 to May 15, 2025.
47 unchanged sentences
Indenture, dated as of March 5, 2021, between Haemonetics Corporation and U.S.
−Removed: Bank National Association, as trustee (filed as Exhibit 4.1 to the Company’s Form 8-K dated March 5, 2021 and incorporated herein by reference).
+Added: Bank National Trust Company, Association, as trustee (filed as Exhibit 4.1 to the Company’s Form 8-K dated March 5, 2021 and incorporated herein by reference).
Form of certificate representing the 0.00% Convertible Senior Notes due 2026 (included as Exhibit A to Exhibit 4D) (filed as Exhibit 4.2 to the Company’s Form 8-K dated March 5, 2021 and incorporated herein by reference).
+Added: Indenture, dated as of May 28, 2024, between Haemonetics Corporation and U.S.
+Added: Bank National Trust Company, Association, as trustee.
+Added: (filed as Exhibit 4.1 to the Company’s Form 8-K dated May 29, 2024 and incorporated herein by reference).
+Added: Form of certificate representing the 2.50% Convertible Senior Notes due 2029 (included as Exhibit A to Exhibit 4.1) (filed as Exhibit 4.2 to the Company’s Form 8-K dated May 29, 2024 and incorporated herein by reference).
Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan, reflecting amendments dated July 31, 2008, July 29, 2009, July 21, 2011, November 30, 2012, July 24, 2013, January 21, 2014, and July 23, 2014 (filed as Exhibit 10.1 to the Company’s Form 8-K dated July 25, 2014 and incorporated herein by reference) (2).
78 unchanged sentences
Lease, dated April 15, 2015, by and between OpSens Inc.
−Removed: and 1405 PTQM S.E.C., for property located at 750, Boulevard du Technologique, Quebec.
+Added: and 1405 PTQM S.E.C., for property located at 750, Boulevard du Technologique, Quebec (filed as Exhibit 10.39 to the Company’s Form 10-K for the fiscal year ended March 30, 2024 and incorporated herein by reference).
1 to Lease, dated December 5, 2022, by and between OpSens Inc.
−Removed: and 1405 PTQM S.E.C, for property located at 750, Boulevard du Technologique, Quebec.
+Added: and 1405 PTQM S.E.C, for property located at 750, Boulevard du Technologique, Quebec (filed as Exhibit 10.40 to the Company’s Form 10-K for the fiscal year ended March 30, 2024 and incorporated herein by reference).
2 to Lease, dated May 1, 2023, by and between OpSens Inc.
−Removed: and 1405 PTQM S.E.C, for property located at 750, Boulevard du Technologique, Quebec.
+Added: and 1405 PTQM S.E.C, for property located at 750, Boulevard du Technologique, Quebec (filed as Exhibit 10.41 to the Company’s Form 10-K for the fiscal year ended March 30, 2024 and incorporated herein by reference).
Form of Confirmation of Call Option Transaction (filed as Exhibit 10.1 to the Company’s Form 8-K dated as of March 5, 2021 and incorporated herein by reference).
Form of Confirmation of Additional Call Option Transaction (filed as Exhibit 10.1 to the Company’s Form 8-K dated as of March 16, 2021 and incorporated herein by reference).
−Removed: Form of Voting and Support Agreement (filed as Exhibit 10.1 to the Company’s Form 8-K/A dated October 12, 2023 and incorporated herein by reference) (1).
−Removed: Securities Trading Policy (2).
+Added: Form of Confirmation of Base Call Option Transaction (filed as Exhibit 10.1 to the Company’s Form 8-K dated May 29, 2024 and incorporated herein by reference).
+Added: Form of Confirmation of Additional Call Option Transaction (filed as Exhibit 10.2 to the Company’s Form 8-K dated May 29, 2024 and incorporated herein by reference).
+Added: Securities Trading Policy (filed as Exhibit 19.1 to the Company’s Form 10-K for the fiscal year ended March 30, 2024 and incorporated herein by reference) (2).
Subsidiaries of the Company.
6 unchanged sentences
Certification Pursuant to 18 United States Code Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, of James D’Arecca, Executive Vice President, Chief Financial Officer of the Company.
−Removed: Compensation Recovery Policy (2).
+Added: Compensation Recovery Policy (filed as Exhibit 97.1 to the Company’s Form 10-K for the fiscal year ended March 30, 2024 and incorporated herein by reference).
101* The following materials from Haemonetics Corporation on Form 10-K for the year ended March 29, 2025, formatted in inline Extensible Business Reporting Language (XBRL) includes:
36 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.